Loading…

Prevalence and features of headache in Parkinson’s disease: the role of dopamine

Introduction Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, but dopamine also plays a role in the pathophysiology of migraine. Objective The aim of this study is to assess lifetime and previous year prevalence rates of headache in P...

Full description

Saved in:
Bibliographic Details
Published in:Neurological sciences 2024-12, Vol.45 (12), p.5749-5756
Main Authors: Giglio, Augusta, Russo, Cinzia Valeria, Riccio, Gabriele, Braca, Simone, Cretella, Gennaro, Stornaiuolo, Antonio, Baratto, Luigi, Marano, Enrico, De Michele, Giuseppe, De Rosa, Anna
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c256t-3bf6787123116e16aa04a86b3d90eac6cd1b503866281592bb7779e277411483
container_end_page 5756
container_issue 12
container_start_page 5749
container_title Neurological sciences
container_volume 45
creator Giglio, Augusta
Russo, Cinzia Valeria
Riccio, Gabriele
Braca, Simone
Cretella, Gennaro
Stornaiuolo, Antonio
Baratto, Luigi
Marano, Enrico
De Michele, Giuseppe
De Rosa, Anna
description Introduction Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, but dopamine also plays a role in the pathophysiology of migraine. Objective The aim of this study is to assess lifetime and previous year prevalence rates of headache in PD patients compared with controls. Patients and methods We enrolled 101 patients (57 M and 44 W) and 101 controls (62 M and 39 W), comparable for age and gender, who underwent a semi-structured questionnaire to assess the occurrence and the features of headache, and Beck Depression Inventory (BDI). Results We did not find any significant differences in the overall prevalence of lifetime and last 12-month headache between the two groups, as well as lifetime and last year tension-type headache (TTH) and migraine. Patients, especially those suffering from migraine and treated with dopamine agonists (DA), more frequently showed headache remission after the onset of motor symptoms compared to the age-related remission observed in controls ( p  = 0.001). Patients affected by headache were less frequently treated with DA in comparison with those without ( p  = 0.051). Depression of mood was more severe among PD patients with migraine than with TTH ( p  = 0.021). PD patients with headache exhibiting the akinetic-rigid subtype more frequently reported motor fluctuations than those presenting with tremor-dominant disease ( p  = 0.040). Conclusions The prevalence of headache in PD follows that described in the general population, but dopaminergic pathway degeneration, loss of dopamine activation on the trigeminal-vascular system, and DA treatment might favor migraine improvement and remission in PD patients.
doi_str_mv 10.1007/s10072-024-07818-9
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3118835586</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3118835586</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-3bf6787123116e16aa04a86b3d90eac6cd1b503866281592bb7779e277411483</originalsourceid><addsrcrecordid>eNp9kMtKxDAUhoMoznh5ARdScOOmmluT1J0M3mDAQWYf0vbU6dimY9IK7nwNX88nMWNHBRducgLnO19yfoSOCD4jGMtzvz5pjCmPsVRExekWGpMkxTHjUm1v7kRJPkJ73i8xxoQTtotGLOWMEoXH6GHm4MXUYHOIjC2iEkzXO_BRW0YLMIXJFxBVNpoZ91RZ39qPt3cfFZUH4-Ei6kLXtTWs8aJdmaaycIB2SlN7ONzUfTS_vppPbuPp_c3d5HIa5zQRXcyyUkglCWWECCDCGMyNEhkrUgwmF3lBsgQzJQRVYRGaZVLKFKiUnBCu2D46HbQr1z734DvdVD6HujYW2t7roFWKJYkSAT35gy7b3tnwuUBRobAIvkDRgcpd672DUq9c1Rj3qgnW66j1ELgOgeuvwHUaho436j5roPgZ-U44AGwAfGjZR3C_b_-j_QQe5InL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3126806483</pqid></control><display><type>article</type><title>Prevalence and features of headache in Parkinson’s disease: the role of dopamine</title><source>Springer Nature</source><creator>Giglio, Augusta ; Russo, Cinzia Valeria ; Riccio, Gabriele ; Braca, Simone ; Cretella, Gennaro ; Stornaiuolo, Antonio ; Baratto, Luigi ; Marano, Enrico ; De Michele, Giuseppe ; De Rosa, Anna</creator><creatorcontrib>Giglio, Augusta ; Russo, Cinzia Valeria ; Riccio, Gabriele ; Braca, Simone ; Cretella, Gennaro ; Stornaiuolo, Antonio ; Baratto, Luigi ; Marano, Enrico ; De Michele, Giuseppe ; De Rosa, Anna</creatorcontrib><description>Introduction Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, but dopamine also plays a role in the pathophysiology of migraine. Objective The aim of this study is to assess lifetime and previous year prevalence rates of headache in PD patients compared with controls. Patients and methods We enrolled 101 patients (57 M and 44 W) and 101 controls (62 M and 39 W), comparable for age and gender, who underwent a semi-structured questionnaire to assess the occurrence and the features of headache, and Beck Depression Inventory (BDI). Results We did not find any significant differences in the overall prevalence of lifetime and last 12-month headache between the two groups, as well as lifetime and last year tension-type headache (TTH) and migraine. Patients, especially those suffering from migraine and treated with dopamine agonists (DA), more frequently showed headache remission after the onset of motor symptoms compared to the age-related remission observed in controls ( p  = 0.001). Patients affected by headache were less frequently treated with DA in comparison with those without ( p  = 0.051). Depression of mood was more severe among PD patients with migraine than with TTH ( p  = 0.021). PD patients with headache exhibiting the akinetic-rigid subtype more frequently reported motor fluctuations than those presenting with tremor-dominant disease ( p  = 0.040). Conclusions The prevalence of headache in PD follows that described in the general population, but dopaminergic pathway degeneration, loss of dopamine activation on the trigeminal-vascular system, and DA treatment might favor migraine improvement and remission in PD patients.</description><identifier>ISSN: 1590-1874</identifier><identifier>ISSN: 1590-3478</identifier><identifier>EISSN: 1590-3478</identifier><identifier>DOI: 10.1007/s10072-024-07818-9</identifier><identifier>PMID: 39432180</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Age ; Aged ; Depression - epidemiology ; Dopamine ; Dopamine - metabolism ; Dopamine receptors ; Female ; Headache ; Headache - epidemiology ; Headaches ; Humans ; Male ; Medicine ; Medicine &amp; Public Health ; Mental depression ; Middle Aged ; Migraine ; Movement disorders ; Neurodegeneration ; Neurodegenerative diseases ; Neurology ; Neuroradiology ; Neurosurgery ; Original Article ; Parkinson Disease - complications ; Parkinson Disease - epidemiology ; Parkinson's disease ; Prevalence ; Psychiatric Status Rating Scales ; Psychiatry ; Remission ; Remission (Medicine) ; Substantia nigra ; Tremor ; Vascular system</subject><ispartof>Neurological sciences, 2024-12, Vol.45 (12), p.5749-5756</ispartof><rights>Fondazione Società Italiana di Neurologia 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. Fondazione Società Italiana di Neurologia.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-3bf6787123116e16aa04a86b3d90eac6cd1b503866281592bb7779e277411483</cites><orcidid>0000-0002-5618-2478</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39432180$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giglio, Augusta</creatorcontrib><creatorcontrib>Russo, Cinzia Valeria</creatorcontrib><creatorcontrib>Riccio, Gabriele</creatorcontrib><creatorcontrib>Braca, Simone</creatorcontrib><creatorcontrib>Cretella, Gennaro</creatorcontrib><creatorcontrib>Stornaiuolo, Antonio</creatorcontrib><creatorcontrib>Baratto, Luigi</creatorcontrib><creatorcontrib>Marano, Enrico</creatorcontrib><creatorcontrib>De Michele, Giuseppe</creatorcontrib><creatorcontrib>De Rosa, Anna</creatorcontrib><title>Prevalence and features of headache in Parkinson’s disease: the role of dopamine</title><title>Neurological sciences</title><addtitle>Neurol Sci</addtitle><addtitle>Neurol Sci</addtitle><description>Introduction Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, but dopamine also plays a role in the pathophysiology of migraine. Objective The aim of this study is to assess lifetime and previous year prevalence rates of headache in PD patients compared with controls. Patients and methods We enrolled 101 patients (57 M and 44 W) and 101 controls (62 M and 39 W), comparable for age and gender, who underwent a semi-structured questionnaire to assess the occurrence and the features of headache, and Beck Depression Inventory (BDI). Results We did not find any significant differences in the overall prevalence of lifetime and last 12-month headache between the two groups, as well as lifetime and last year tension-type headache (TTH) and migraine. Patients, especially those suffering from migraine and treated with dopamine agonists (DA), more frequently showed headache remission after the onset of motor symptoms compared to the age-related remission observed in controls ( p  = 0.001). Patients affected by headache were less frequently treated with DA in comparison with those without ( p  = 0.051). Depression of mood was more severe among PD patients with migraine than with TTH ( p  = 0.021). PD patients with headache exhibiting the akinetic-rigid subtype more frequently reported motor fluctuations than those presenting with tremor-dominant disease ( p  = 0.040). Conclusions The prevalence of headache in PD follows that described in the general population, but dopaminergic pathway degeneration, loss of dopamine activation on the trigeminal-vascular system, and DA treatment might favor migraine improvement and remission in PD patients.</description><subject>Age</subject><subject>Aged</subject><subject>Depression - epidemiology</subject><subject>Dopamine</subject><subject>Dopamine - metabolism</subject><subject>Dopamine receptors</subject><subject>Female</subject><subject>Headache</subject><subject>Headache - epidemiology</subject><subject>Headaches</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Mental depression</subject><subject>Middle Aged</subject><subject>Migraine</subject><subject>Movement disorders</subject><subject>Neurodegeneration</subject><subject>Neurodegenerative diseases</subject><subject>Neurology</subject><subject>Neuroradiology</subject><subject>Neurosurgery</subject><subject>Original Article</subject><subject>Parkinson Disease - complications</subject><subject>Parkinson Disease - epidemiology</subject><subject>Parkinson's disease</subject><subject>Prevalence</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychiatry</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><subject>Substantia nigra</subject><subject>Tremor</subject><subject>Vascular system</subject><issn>1590-1874</issn><issn>1590-3478</issn><issn>1590-3478</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kMtKxDAUhoMoznh5ARdScOOmmluT1J0M3mDAQWYf0vbU6dimY9IK7nwNX88nMWNHBRducgLnO19yfoSOCD4jGMtzvz5pjCmPsVRExekWGpMkxTHjUm1v7kRJPkJ73i8xxoQTtotGLOWMEoXH6GHm4MXUYHOIjC2iEkzXO_BRW0YLMIXJFxBVNpoZ91RZ39qPt3cfFZUH4-Ei6kLXtTWs8aJdmaaycIB2SlN7ONzUfTS_vppPbuPp_c3d5HIa5zQRXcyyUkglCWWECCDCGMyNEhkrUgwmF3lBsgQzJQRVYRGaZVLKFKiUnBCu2D46HbQr1z734DvdVD6HujYW2t7roFWKJYkSAT35gy7b3tnwuUBRobAIvkDRgcpd672DUq9c1Rj3qgnW66j1ELgOgeuvwHUaho436j5roPgZ-U44AGwAfGjZR3C_b_-j_QQe5InL</recordid><startdate>20241201</startdate><enddate>20241201</enddate><creator>Giglio, Augusta</creator><creator>Russo, Cinzia Valeria</creator><creator>Riccio, Gabriele</creator><creator>Braca, Simone</creator><creator>Cretella, Gennaro</creator><creator>Stornaiuolo, Antonio</creator><creator>Baratto, Luigi</creator><creator>Marano, Enrico</creator><creator>De Michele, Giuseppe</creator><creator>De Rosa, Anna</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5618-2478</orcidid></search><sort><creationdate>20241201</creationdate><title>Prevalence and features of headache in Parkinson’s disease: the role of dopamine</title><author>Giglio, Augusta ; Russo, Cinzia Valeria ; Riccio, Gabriele ; Braca, Simone ; Cretella, Gennaro ; Stornaiuolo, Antonio ; Baratto, Luigi ; Marano, Enrico ; De Michele, Giuseppe ; De Rosa, Anna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-3bf6787123116e16aa04a86b3d90eac6cd1b503866281592bb7779e277411483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Age</topic><topic>Aged</topic><topic>Depression - epidemiology</topic><topic>Dopamine</topic><topic>Dopamine - metabolism</topic><topic>Dopamine receptors</topic><topic>Female</topic><topic>Headache</topic><topic>Headache - epidemiology</topic><topic>Headaches</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Mental depression</topic><topic>Middle Aged</topic><topic>Migraine</topic><topic>Movement disorders</topic><topic>Neurodegeneration</topic><topic>Neurodegenerative diseases</topic><topic>Neurology</topic><topic>Neuroradiology</topic><topic>Neurosurgery</topic><topic>Original Article</topic><topic>Parkinson Disease - complications</topic><topic>Parkinson Disease - epidemiology</topic><topic>Parkinson's disease</topic><topic>Prevalence</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychiatry</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><topic>Substantia nigra</topic><topic>Tremor</topic><topic>Vascular system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giglio, Augusta</creatorcontrib><creatorcontrib>Russo, Cinzia Valeria</creatorcontrib><creatorcontrib>Riccio, Gabriele</creatorcontrib><creatorcontrib>Braca, Simone</creatorcontrib><creatorcontrib>Cretella, Gennaro</creatorcontrib><creatorcontrib>Stornaiuolo, Antonio</creatorcontrib><creatorcontrib>Baratto, Luigi</creatorcontrib><creatorcontrib>Marano, Enrico</creatorcontrib><creatorcontrib>De Michele, Giuseppe</creatorcontrib><creatorcontrib>De Rosa, Anna</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Neurological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giglio, Augusta</au><au>Russo, Cinzia Valeria</au><au>Riccio, Gabriele</au><au>Braca, Simone</au><au>Cretella, Gennaro</au><au>Stornaiuolo, Antonio</au><au>Baratto, Luigi</au><au>Marano, Enrico</au><au>De Michele, Giuseppe</au><au>De Rosa, Anna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence and features of headache in Parkinson’s disease: the role of dopamine</atitle><jtitle>Neurological sciences</jtitle><stitle>Neurol Sci</stitle><addtitle>Neurol Sci</addtitle><date>2024-12-01</date><risdate>2024</risdate><volume>45</volume><issue>12</issue><spage>5749</spage><epage>5756</epage><pages>5749-5756</pages><issn>1590-1874</issn><issn>1590-3478</issn><eissn>1590-3478</eissn><abstract>Introduction Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, but dopamine also plays a role in the pathophysiology of migraine. Objective The aim of this study is to assess lifetime and previous year prevalence rates of headache in PD patients compared with controls. Patients and methods We enrolled 101 patients (57 M and 44 W) and 101 controls (62 M and 39 W), comparable for age and gender, who underwent a semi-structured questionnaire to assess the occurrence and the features of headache, and Beck Depression Inventory (BDI). Results We did not find any significant differences in the overall prevalence of lifetime and last 12-month headache between the two groups, as well as lifetime and last year tension-type headache (TTH) and migraine. Patients, especially those suffering from migraine and treated with dopamine agonists (DA), more frequently showed headache remission after the onset of motor symptoms compared to the age-related remission observed in controls ( p  = 0.001). Patients affected by headache were less frequently treated with DA in comparison with those without ( p  = 0.051). Depression of mood was more severe among PD patients with migraine than with TTH ( p  = 0.021). PD patients with headache exhibiting the akinetic-rigid subtype more frequently reported motor fluctuations than those presenting with tremor-dominant disease ( p  = 0.040). Conclusions The prevalence of headache in PD follows that described in the general population, but dopaminergic pathway degeneration, loss of dopamine activation on the trigeminal-vascular system, and DA treatment might favor migraine improvement and remission in PD patients.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>39432180</pmid><doi>10.1007/s10072-024-07818-9</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-5618-2478</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1590-1874
ispartof Neurological sciences, 2024-12, Vol.45 (12), p.5749-5756
issn 1590-1874
1590-3478
1590-3478
language eng
recordid cdi_proquest_miscellaneous_3118835586
source Springer Nature
subjects Age
Aged
Depression - epidemiology
Dopamine
Dopamine - metabolism
Dopamine receptors
Female
Headache
Headache - epidemiology
Headaches
Humans
Male
Medicine
Medicine & Public Health
Mental depression
Middle Aged
Migraine
Movement disorders
Neurodegeneration
Neurodegenerative diseases
Neurology
Neuroradiology
Neurosurgery
Original Article
Parkinson Disease - complications
Parkinson Disease - epidemiology
Parkinson's disease
Prevalence
Psychiatric Status Rating Scales
Psychiatry
Remission
Remission (Medicine)
Substantia nigra
Tremor
Vascular system
title Prevalence and features of headache in Parkinson’s disease: the role of dopamine
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T00%3A08%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20and%20features%20of%20headache%20in%20Parkinson%E2%80%99s%20disease:%20the%20role%20of%20dopamine&rft.jtitle=Neurological%20sciences&rft.au=Giglio,%20Augusta&rft.date=2024-12-01&rft.volume=45&rft.issue=12&rft.spage=5749&rft.epage=5756&rft.pages=5749-5756&rft.issn=1590-1874&rft.eissn=1590-3478&rft_id=info:doi/10.1007/s10072-024-07818-9&rft_dat=%3Cproquest_cross%3E3118835586%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c256t-3bf6787123116e16aa04a86b3d90eac6cd1b503866281592bb7779e277411483%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3126806483&rft_id=info:pmid/39432180&rfr_iscdi=true